Deciding on second- or third-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) based on the presence of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)

被引：0
|
作者：
Porta, Rut
Terrasa, Josefa
Rolfo, Cristian
Gonzalez Larriba, Jose Luis
Garcia Campelo, Rosario
Mesia, Carlos
Pallares, Cinta
Lianes, Pilar
Queralt, Cristina
Rosell, Rafael
机构：
[1] Hosp Josep Trueta, Med Oncol Serv, Catalan Inst Oncol, Girona, Spain
[2] Hosp Son Dureta, Med Oncol Serv, Mallorca, Spain
[3] Med Oncol Serv, Clin Rotger, Mallorca, Spain
[4] Hosp Clin Madrid, Med Oncol Serv, Madrid, Spain
[5] Hosp Juan Canalejo, Med Oncol Serv, La Coruna, Spain
[6] Hosp del Mar, Med Oncol Serv, Barcelona, Spain
[7] Hosp Santa Creu & Sant Pau, Med Oncol Serv, Barcelona, Spain
[8] Hosp Mataro, Med Oncol Serv, Mataro, Spain
[9] Hosp Germans Trias & Pujol, Med Oncol Serv, Catalan Inst Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：215 / 216
页数：2
相关论文
共 50 条
  • [31] Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jaenne, Pasi A.
    Johnson, Bruce E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4416S - 4420S
  • [32] CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Domingues, Pedro Masson
    Montella, Tatiane
    Baldotto, Clarissa Serodio
    Siqueira, Mariana
    Zukin, Mauro
    Ferreira, Carlos Gil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S169 - S169
  • [33] Rare and complex mutations of epidermal growth factor receptor (EGFR) and efficacy of tyrosine kinase inhibitor (TKI) in patients with non-small cell lung cancer (NSCLC).
    Keam, Bhumsuk
    Kim, Dong-Wan
    Park, Jin Hyun
    Lee, Jeong-Ok
    Kim, Tae Min
    Lee, Se-Hoon
    Jeon, Yoon-Kyung
    Chung, Doo Hyun
    Heo, Dae Seog
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Mutation in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer (NSCLC)
    Tsai, C
    Chiu, C
    Chou, T
    Li, L
    Chang, K
    Chen, Y
    Tsai, S
    Perng, R
    [J]. LUNG CANCER, 2005, 49 : S113 - S113
  • [35] A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)-in non-small-cell lung cancer (NSCLC)
    Popper H.
    Wrba F.
    Gruber-Mösenbacher U.
    Hulla W.
    Pirker R.
    Hilbe W.
    Studnicka M.
    Mohn-Staudner A.
    Ploner F.
    [J]. memo - Magazine of European Medical Oncology, 2011, 4 (4) : 248 - 253
  • [36] The Efficacy Of The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors On Minor Mutations Compared With Classical Active Mutations In Patients With Non-Small-Cell Lung Cancer Harboring EGFR Mutations
    Makino, H.
    Yamada, T.
    Takai, M.
    Munakata, Y.
    Kobayashi, H.
    Nakashima, K.
    Katsurada, N.
    Misawa, M.
    Kaneko, N.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [37] Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
    Okano, Yoshio
    Ando, Masahiko
    Asami, Kazuhiro
    Fukuda, Masaaki
    Nakagawa, Hideyuki
    Ibata, Hidenori
    Kozuki, Toshiyuki
    Endo, Tateo
    Tamura, Atsuhisa
    Kamimura, Mitsuhiro
    Sakamoto, Kazuhiro
    Yoshimi, Michihiro
    Soejima, Yoshifumi
    Tomizawa, Yoshio
    Isa, Shunichi
    Takada, Minoru
    Saka, Hideo
    Kubo, Akihito
    Kawaguchi, Tomoya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC).
    Sonobe, M
    Katakura, H
    Adachi, T
    Wada, H
    Tanaka, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 637S - 637S
  • [39] MUTATIONS IN THE EPIDERMAL GROWTH FACTOR RECEPTOR GENE IN NON-SMALL-CELL LUNG CANCER PATIENTS AND EGFR SERUM LEVELS
    Romero-Ventosa, E. Y.
    Rodriguez Rodriguez, M.
    Gonzalez Costas, S.
    GonzAlez-PiNeiro, A.
    Blanco-Prieto, S.
    Paez de La Cadena, M.
    Arias Santos, I.
    Leboreiro Enriquez, B.
    Bernardez Ferran, B.
    Brozos, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 92 - 92
  • [40] EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS (TKIS) ERLOTINIB AND GEFITINIB IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER (NSCLC)
    Naskhletashvili, D. R.
    Gorbounova, V.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 435 - 435
12345